Aviado · Research
Longevity Daily
Thursday, October 8, 2026
Listen
Today's Brief
Today's standout story is a landmark: the first large randomized trial testing statins for primary prevention in healthy older adults has reported back, potentially settling a decades-long debate in preventive cardiology. An Australian RCT also found four weeks of dietary change cut biological age by up to four years in adults over 65 — with important fine print worth reading. Creatine's muscle-building evidence holds in midlife even without a gym, and Big Pharma has now launched a trial to test semaglutide in healthy older adults. Our Aviado analysis arms you with a protocol for testing whether boswellia is actually moving your inflammation numbers.
10 stories5 peer-reviewed3 trials1 Aviado original
Cognitive Health & Neuroprotection
Low Cognitive Scores in Your 60s Predict Higher Stroke Risk, New Data Shows
If your memory or processing speed is dipping in your 60s, new research suggests your stroke risk is already creeping up alongside it. A study published in Neurology links lower scores in global cognition, episodic memory, and perceptual speed during the 60s to significantly elevated stroke risk in the following years. The finding strengthens the case for cognitive screening not just as a dementia early-warning tool, but as a vascular one — and it makes annual brain health monitoring more urgent, not optional.
Read more →Exercise Slows Epigenetic Aging and Sharpens Cognition in Cancer Survivors
Cancer survivors who underwent chemo or radiation carry more senescent cells than age-matched peers — and that extra burden means they are biologically aging faster. New evidence shows regular exercise measurably slows epigenetic aging in this population while also improving cognitive function, likely because exercise upregulates autophagy, the cellular housekeeping process that reduces the rate at which cells turn senescent. For survivors — or anyone concerned about accelerated aging — this adds another data point for exercise as a legitimate anti-aging intervention, not just a health habit.
Read more →Supplements & Compounds
Creatine Builds Lean Muscle in Midlife — Even Without Exercise, New Trial Finds
A 12-week controlled trial found that adults over 45 who supplemented with creatine gained lean mass — even those not following a structured exercise program. The finding matters because sarcopenia, the slow loss of muscle that begins in your 40s, is one of the strongest predictors of functional decline later in life. The gains are more pronounced with resistance training, but for a cheap, well-tolerated supplement, creatine's evidence base in midlife is now considerably stronger.
Read more →Retinoids, Niacinamide, and Topical Rapamycin Lead the Rankings for Skin Anti-Aging
A new review from Chinese dermatology and military medicine researchers ranked 47 classes of candidate anti-aging skin compounds by the biological mechanisms they target — from oxidative stress and telomere attrition to cellular senescence. Retinoids, niacinamide, and topical rapamycin emerged at the top of the evidence hierarchy across multiple pathways. If you're allocating skincare budget, this review is the closest thing to an evidence-based buying guide currently available.
Read more →Boswellia Works — But Only If You Test to See
Boswellia serrata is one of the most-studied natural anti-inflammatory supplements — but Aviado's analysis reveals a sharp divide that most users miss: it reliably drops inflammatory cytokines like TNF-α and IL-6 by 30–50% in some people, and does almost nothing in others. The difference isn't dose or product quality; it's your baseline inflammation level, which you can only know by testing. The protocol is clear: 500–1,000mg daily of standardized extract (≥30% boswellic acids, 10–20% AKBA) for 90 days, with hsCRP and TNF-α tested before and after — your bloodwork will tell you whether you're a responder.
Read the full Aviado analysis →Research & Papers
First Large RCT of Statins for Healthy Older Adults Reports Back — and It Could Change Everything
For decades, cardiologists have debated whether healthy older adults — those without established cardiovascular disease — should be taking statins at all. A large new randomized controlled trial of atorvastatin, described as the first ever of its kind, is now reporting results on whether statins can help people over 65 live longer in good health. If the data support primary prevention in older patients, it would represent one of the biggest shifts in preventive medicine guidelines in a generation — touching tens of millions of people currently told that statins are not yet for them. The emerging findings deserve your full attention.
Read more →Four Weeks on a Different Diet Slashed Biological Age by Up to 4 Years — Read the Fine Print
Researchers at the University of Sydney randomized 104 adults aged 65–75 into four different diets for just four weeks, then measured biological age using epigenetic clocks — and found reductions of up to 4 years in the top-performing group. The results are striking, but the author flags critical caveats: epigenetic clocks don't all measure the same thing, and short-term dietary shifts may look better on a methylation clock than they perform in long-term health outcomes. Still, the trial's rigorous design makes it worth reading carefully before you overhaul your plate.
Read more →Lifestyle & Nutrition
Your Morning Coffee May Be Activating an Ancient Anti-Aging Pathway
Researchers at Queen Mary University of London have identified a mechanism for caffeine's repeatedly observed anti-aging associations: it activates a biological switch — conserved from yeast to humans — that modulates the TORC1 growth pathway, the same target as rapamycin. Contrary to earlier assumptions, caffeine doesn't inhibit TORC1 directly but flips this upstream regulator, pushing cells toward maintenance rather than growth. The work is still largely in yeast and cell models, so don't swap your rapamycin for an espresso just yet — but it adds genuine mechanistic grounding to coffee's longevity story.
Read more →Industry & Policy
Big Pharma Is Betting on Longevity — And Semaglutide Could Be the Next Experiment
Business Insider maps the strategic shift underway in Big Pharma: major drug companies are quietly positioning approved drugs — especially GLP-1s like semaglutide — as potential longevity medicines, not just metabolic treatments. The critical test is the newly funded PROSPR trial, which will give semaglutide to healthy older adults with no diabetes or obesity and track what happens to their aging trajectory. Regulators would need far more than early signals to approve a drug for aging itself, but the commercial and scientific investment is accelerating fast.
Read more →Nonprofit Hospitals Are Charging $5,500+ for Longevity Clinics — and Raising Hard Questions
Major nonprofit hospital systems, including Northwestern, are now running longevity clinics that charge $5,500 or more for comprehensive checkups — and critics are asking hard questions about whether tax-exempt institutions should be offering premium-access preventive medicine. The tension cuts both ways: these programs attract high-net-worth patients and generate revenue that can subsidize other care, but they also raise serious questions about health equity and what 'charity care' actually means in practice. If you're considering a longevity clinic, this piece puts the business model — and the ethical questions around it — in plain view.
Read more →